阿尔茨海默病致病机制及治疗药物研究新进展  

Pathogenesis and New Therapeutic Drugs of Alzheimer Disease

作　　者：王其琼 吕俊玲[1] 胡咏川[1] 刘蕾[1] WANG Qi-qiong;Lü Jun-ling;HU Yong-chuan;LIU Lei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing 100730,China;Department of Pharmacy Administration&Clinical Pharmacy,School of Pharmaceutical Science,Peking University,Beijing 100191,China)

机构地区：[1]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,药物临床风险与个体化应用评价北京市重点实验室,北京100730 [2]北京大学医学部药学院药事管理与临床药学系,北京100191

出　　处：《中国药学杂志》2020年第23期1939-1947,共9页Chinese Pharmaceutical Journal

摘　　要：阿尔茨海默病(Alzheimer′s disease,AD)是一种神经退行性疾病。AD特征性病理变化包括大脑β淀粉样蛋白(β-amyloid,Aβ)沉积形成老年斑(plaque),tau蛋白过度磷酸化造成神经纤维缠结(neurofibrillary tangles,NFT),以及神经元丢失。AD的确切发病机制尚未明确,全球仍缺乏治愈AD的药物或方法。AD治疗药物的研究进展缓慢,目前的研发方向仍以抗Aβ和tau蛋白为主,其他多个方向并存,如抗炎、改善代谢、改善血管功能及联合疗法等。笔者对AD的致病机制和治疗药物研究进展作一综述。Alzheimer′s disease(AD) is a neurodegenerative disease. Pathologic hallmarks of AD include senile plaques comprising β-amyloid(Aβ) proteins along with many other misfolded proteins and neurofibrillary tangles formed by hyperphosphorylated tau protein aggregates. The exact pathogenesis of AD has not yet been clarified, and there are still no methods or drugs to cure AD worldwide. The development progress of AD treatment drugs is slow. Anti-Aβ and anti-Tau proteins are the main direction of research and development, and multiple directions coexist, such as anti-inflammation, improving metabolism and vascular function, and combination therapy. This article reviews the research progress of the pathogenic mechanism and therapeutic drugs of AD.

关 键 词：阿尔茨海默病 发病机制 治疗药物 

分 类 号：R965[医药卫生—药理学]